Overview

This trial is active, not recruiting.

Conditions stable angina, myocardial infarction, coronary heart disease, heart failure, stroke, death, sudden, cardiac, peripheral arterial disease, atrial fibrillation, bleeding
Sponsor University College, London
Collaborator Wellcome Trust
Start date September 2013
End date December 2013
Trial size 51703 participants
Trial identifier NCT02244853, 086091/Z/08/Z, 12_153R_IP24, RP-PG-0407-10314

Summary

The Cardiovascular disease research using Linked Bespoke studies and Electronic Records (CALIBER) e-health database was the data resource for this study. CALIBER links patient records from four different data sources: Clinical Practice Research Database (CPRD), MINAP (Myocardial Ischaemia National Audit Project registry) Hospital Episodes Statistics (HES), the Office for National Statistics (ONS).

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective

Primary Outcomes

Measure
Risk of cardiovascular diseases in patients with low and high heart rate and stable coronary artery disease
time frame: expected average of 3 years

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: - Aged >=30 years at study entry ->=1 year registration prior to the 'index date' Exclusion Criteria: - Free from previous atherosclerotic events - No heart rate measurement after their 'index date' of eligibility to entry the study

Additional Information

Official title Association of Heart Rate With Cardiovascular Disease Prognosis of Patients With Stable Coronary Artery Disease: A CALIBER Study
Description This study is part of the CALIBER (Cardiovascular disease research using linked bespoke studies and electronic records) programme funded over 5 years from the NIHR and Wellcome Trust. The central theme of the CALIBER research is linkage of the Myocardial Ischaemia National Audit Project (MINAP) with primary care (GPRD) and other resources. The overarching aim of CALIBER is to better understand the aetiology and prognosis of specific coronary phenotypes across a range of causal domains, particularly where electronic records provide a contribution beyond traditional studies. CALIBER has received both Ethics approval (ref 09/H0810/16) and ECC approval (ref ECC 2-06(b)/2009 CALIBER dataset).
Trial information was received from ClinicalTrials.gov and was last updated in September 2014.
Information provided to ClinicalTrials.gov by University College, London.